{'52WeekChange': 0.33846164,
 'SandP52WeekChange': 0.0644362,
 'address1': '900 Northbrook Drive',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.45,
 'askSize': 1300,
 'averageDailyVolume10Day': 286437,
 'averageVolume': 353258,
 'averageVolume10days': 286437,
 'beta': 4.866106,
 'beta3Year': None,
 'bid': 3.45,
 'bidSize': 1300,
 'bookValue': 1.128,
 'category': None,
 'circulatingSupply': None,
 'city': 'Trevose',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.52,
 'dayLow': 3.33,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.304,
 'enterpriseToRevenue': 5.295,
 'enterpriseValue': 127298304,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.7047143,
 'fiftyTwoWeekHigh': 4.63,
 'fiftyTwoWeekLow': 1.43,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 26808573,
 'forwardEps': -0.5,
 'forwardPE': -6.96,
 'fromCurrency': None,
 'fullTimeEmployees': 71,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.1091,
 'heldPercentInstitutions': 0.68151003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/strongbridgebio.com',
 'longBusinessSummary': 'Strongbridge Biopharma plc, a commercial-stage '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization of therapies for rare diseases '
                        "with unmet needs. The company's commercial products "
                        'include Keveyis, an oral carbonic anhydrase inhibitor '
                        'for treating hyperkalemic, hypokalemic, and related '
                        'variants of primary periodic paralysis in the United '
                        'States; and Macrilen, an oral growth hormone '
                        'secretagogue receptor agonist for use in the '
                        'diagnosis of patients with adult growth hormone '
                        'deficiency. Its clinical-stage product candidates are '
                        'Recorlev, a cortisol synthesis inhibitor, which is in '
                        'a Phase III clinical trial that is used for the '
                        "treatment of endogenous Cushing's syndrome; and "
                        'Veldoreotide, a somatostatin analog that completed '
                        'Phase II clinical trial for the treatment of '
                        'acromegaly. The company was formerly known as '
                        'Cortendo plc and changed its name to Strongbridge '
                        'Biopharma plc in September 2015. Strongbridge '
                        'Biopharma plc was founded in 1996 and is based in '
                        'Trevose, Pennsylvania.',
 'longName': 'Strongbridge Biopharma plc',
 'market': 'us_market',
 'marketCap': 188781296,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_22287761',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -43715000,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.44,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.22,
 'phone': '610 254 9200',
 'previousClose': 3.42,
 'priceHint': 4,
 'priceToBook': 3.0851064,
 'priceToSalesTrailing12Months': 7.8518195,
 'profitMargins': -1.8182001,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.52,
 'regularMarketDayLow': 3.33,
 'regularMarketOpen': 3.44,
 'regularMarketPreviousClose': 3.42,
 'regularMarketPrice': 3.44,
 'regularMarketVolume': 117416,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 54247500,
 'sharesPercentSharesOut': 0.0126,
 'sharesShort': 684042,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 387758,
 'shortName': 'Strongbridge Biopharma plc',
 'shortPercentOfFloat': 0.0147,
 'shortRatio': 1.75,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'SBBP',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.028,
 'twoHundredDayAverage': 2.9215467,
 'volume': 117416,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.strongbridgebio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '19053'}